Barrett J. Nehilla, a Senior Scientist at Nexgenia, is the lead author on a recent publication in Analytical Chemistry, an ACS journal. Find the publication here. The work describes Nexgenia’s binary reagent system for protein biomarker isolation.
Nexgenia was awarded a Phase 1 SBIR grant from the National Institute of Allergy and Infectious Disease (NIAID) in February 2016. Nexgenia is collaborating with the Fred Hutchinson Cancer Research Center on this proposal. The project helps to commercialize our reagents for CAR T cell manufacturing.
Nexgenia and Seattle Children’s Research Institute Join Forces to Advance Immunotherapy Research Efforts Developing novel reagents designed to improve the efficiency and effectiveness of cancer immunotherapies Seattle, WA – October 19 – Nexgenia, a privately held biotechnology company focused on the development and manufacture of proprietary polymer-based reagents, is..
Read more
Cancer immunotherapy was highlighted in the Seattle Business Magazine’s December issue. Nexgenia was featured as a company with tools to help the manufacturing process of cell-based cancer immunotherapies. Read the full article here.
Nexgenia was featured in the online news of the Puget Sound Business Journal. Read the article here.
Nexgenia’s new CEO shifts focus to cell separations and immunotherapy product development. Read the press release from the UW C4C below. Nexgenia News Release
